Priming TLR3 and TLR4 in human adipose- and olfactory mucosa-derived mesenchymal stromal cells and comparison of their cytokine secretions.
Adipose tissue
Human olfactory mucosa
Immunomodulation
Mesenchymal stromal cells
Toll-like receptors
Journal
Cytotechnology
ISSN: 0920-9069
Titre abrégé: Cytotechnology
Pays: United States
ID NLM: 8807027
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
12
04
2019
accepted:
12
11
2019
revised:
31
10
2019
pubmed:
4
1
2020
medline:
4
1
2020
entrez:
4
1
2020
Statut:
ppublish
Résumé
Mesenchymal stromal cells (MSCs) have potent immunomodulatory abilities to regulate most of the immune cells. Not only the tissue origin of MSCs can affect their functions, but also their microenvironment can strongly influence their biology, particularly through toll-like receptors (TLR)/ligands interaction. In the present study, we compared MSCs derived from two different sources, i.e. human olfactory ecto-mesenchymal stem cells (OE-MSCs) and adipose tissue (AT-MSCs), in terms of their immunosuppressive effects before and after TLR3 and TLR4 stimulation through low-level and short-term TLR-priming protocol. After isolation and characterization of OE-MSCs and AT-MSCs, flow cytometry analyses were used to assess the expression of TLR3, TLR4 by MSCs. Secretion and expression levels of immune-related genes were analyzed using ELISA and RT-qPCR techniques. Based on the results, the proliferation potential of OE-MSCs was significantly higher than that of AT-MSCs. The gene expression and also protein levels of both TLR3 and TLR4 were significantly higher in OE-MSCs, compared to AT-MSCs. Among the examined cytokines and chemokines, OE-MSCs exhibited significantly higher levels of CCL5, IL-8, and TGF-β production, in comparison with AT-MSCs. However, IL-6 secretion by AT-MSCs was considerably more than that by OE-MSCs. OE-MSCs were only affected by the TLR4 ligand, and IL-8 and IL-6 production levels increased after LPS treatment. However, only IL-8 significantly increased after adding LPS or Poly (I:C) to the AT-MSC media. According to the obtained data, OE-MSCs exhibited a higher proliferative potential and greater expression levels of TLR3 and TLR4 genes, compared to AT-MSCs. However, unlike AT-MSCs, the expression of TLR3 by OE-MSCs was nonfunctional. Finally, based on our findings, OE-MSCs have a stronger secretion of immunosuppressive cytokines both before and after LPS or PIC treatment, compared to AT-MSCs.
Identifiants
pubmed: 31898754
doi: 10.1007/s10616-019-00357-8
pii: 10.1007/s10616-019-00357-8
pmc: PMC7002628
doi:
Types de publication
Journal Article
Langues
eng
Pagination
57-68Subventions
Organisme : Iran University of Medical Sciences
ID : 3933
Références
J Clin Invest. 1998 Jan 15;101(2):311-20
pubmed: 9435302
Gut. 2009 Jul;58(7):929-39
pubmed: 19136511
Blood. 1994 Jan 1;83(1):113-8
pubmed: 8274730
Stem Cells Dev. 2010 Jun;19(6):853-66
pubmed: 19905894
Calcif Tissue Int. 2003 Feb;72(2):135-42
pubmed: 12457262
Stem Cell Res Ther. 2014 Jul 07;5(4):85
pubmed: 25157428
PLoS One. 2014 Jul 08;9(7):e101558
pubmed: 25004159
Front Immunol. 2012 Jul 02;3:182
pubmed: 22783256
Chest. 2000 Apr;117(4):1162-72
pubmed: 10767254
PLoS One. 2010 Apr 26;5(4):e10088
pubmed: 20436665
Sci Rep. 2018 Sep 6;8(1):13325
pubmed: 30190615
Int J Mol Med. 2014 Sep;34(3):695-704
pubmed: 24970492
Cytotechnology. 2015 Oct;67(5):793-807
pubmed: 24798808
Muscle Nerve. 1995 Dec;18(12):1417-26
pubmed: 7477065
Stem Cells. 2008 Jan;26(1):279-89
pubmed: 17962701
Mol Biol Rep. 2013 Mar;40(3):2533-9
pubmed: 23187741
Blood. 2005 Sep 1;106(5):1755-61
pubmed: 15905186
World J Stem Cells. 2014 Nov 26;6(5):552-70
pubmed: 25426252
Int Immunopharmacol. 2017 Jun;47:59-69
pubmed: 28364628
Arthritis Rheum. 2009 Apr;60(4):1006-19
pubmed: 19333946
Lancet. 2004 May 1;363(9419):1439-41
pubmed: 15121408
Mediators Inflamm. 2010;2010:865601
pubmed: 20628526
Exp Hematol. 2002 Jan;30(1):42-8
pubmed: 11823036
J Mol Cell Cardiol. 2007 Jan;42(1):88-97
pubmed: 17101147
J Orthop Res. 1998 Jul;16(4):406-13
pubmed: 9747780
Laryngoscope. 2010 Mar;120(3):546-51
pubmed: 20131365
J Vis Exp. 2011 Aug 22;(54):
pubmed: 21876529
Cell Immunol. 2011;270(2):207-16
pubmed: 21700275
Stem Cells Dev. 2012 Mar 20;21(5):742-56
pubmed: 22128806
Exp Hematol. 1995 Feb;23(2):133-41
pubmed: 7828670
Nat Med. 2009 Jan;15(1):42-9
pubmed: 19098906
J Clin Invest. 2011 Jul;121(7):2808-20
pubmed: 21670501
Stem Cells Dev. 2010 May;19(5):635-44
pubmed: 19761404
Glia. 2013 Mar;61(3):368-82
pubmed: 23281012
J Dent Res. 2013 Sep;92(9):825-32
pubmed: 23867762
Dev Biol. 1997 Jan 1;181(1):64-78
pubmed: 9015265
Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E433-7
pubmed: 12857678
Transplantation. 1974 Apr;17(4):331-40
pubmed: 4150881